Life Sciences Tools and Services

Codexi

Codexi released FY2026 Q1 earnings on May 7 After-Market EST, actual revenue USD 15.25 M (forecast USD 14.44 M), actual EPS USD -0.1 (forecast USD -0.1366)

Codexi to Release FY2026 Q1 Earnings on May 7 After-Market EST, Forecast Revenue USD 14.53 M, EPS USD -0.1366

Codexi released FY2025 Annual Earnings on March 11 After-Market (EST), Actual Revenue USD 70.39 M (Forecast USD 67.28 M), Actual EPS USD -0.5046 (Forecast USD -0.6371)

Codexi released FY2025 Q4 earnings on March 11 After-Market EST, actual revenue USD 38.92 M (forecast USD 35.83 M), actual EPS USD 0.1062 (forecast USD -0.03)

Codexi to Release FY2025 Q4 Earnings on March 11 After-Market EST, Forecast Revenue USD 35.83 M, EPS USD -0.03

Codexi released FY2025 Q3 earnings on November 6 After-Market EST, actual revenue USD 8.601 M (forecast USD 18.52 M), actual EPS USD -0.2173 (forecast USD -0.1485)

Codexi released FY2025 9 Months earnings on November 6 After-Market (EST), actual revenue USD 31.47M, actual EPS USD -0.6264

Codexi to Release FY2025 Q3 Earnings on November 6 After-Market EST, Forecast Revenue USD 18.52 M, EPS USD -0.1485

Codexi released FY2025 Q2 earnings on August 13 After-Market (EST), actual revenue USD 15.33 M (forecast USD 14.18 M), actual EPS USD -0.16 (forecast USD -0.1885)

Codexi released FY2025 Semi-Annual earnings on August 13 After-Market EST, actual revenue USD 22.87 M, actual EPS USD -0.4047

Codexis to Release Q2 2025 Earnings Report

Codexi to Release FY2025 Q2 Earnings on August 13 After-Market EST, Forecast Revenue USD 14.18 M, EPS USD -0.1885

Opaleye Management Inc. Acquires Codexis Inc. Common Stock

Opaleye Management Acquires Codexis Common Stock

Codexis Plans to Attend Jefferies Global Healthcare Conference

Codexi released FY2025 Q1 earnings on May 14 After-Market EST, actual revenue USD 7.543 M (forecast USD 9.663 M), actual EPS USD -0.251 (forecast USD -0.2371)

Codexi to Release FY2025 Q1 Earnings on May 14 After-Market EST, Forecast Revenue USD 9.663 M, EPS USD -0.2371

Codexi released FY2024 Q4 earnings on February 27 After-Market (EST), actual revenue 21.46 M USD (forecast 27.41 M USD), actual EPS -0.1276 USD (forecast -0.0362 USD)

Codexi released FY2024 annual earnings on February 27 After-Market (EST), actual revenue 59.35 M USD (forecast 65.29 M USD), actual EPS -0.8892 USD (forecast -0.7937 USD)

Codexi to Release FY2024 Q4 Earnings on February 27, 2025, After-Market EST; Forecast Revenue 27.41 M USD, EPS -0.0362 USD

NewGenIvf

Agape ATP

Liminatus Pharma

Defiance Daily Target 2X Long RGTI ETF

Tradr 2X Long QBTS Daily ETF

Tradr 2X Long RGTI Daily ETF

Infleqtion

Sunshine Biopharma

Wheeler Real Estate

Defiance 2X Daily Long Pure Quantum ETF

CDXS

ARKG

IBBQ

SBIO

LABU

Codexis maintains a Hold rating with a $2 price target, as analyst Brendan Smith from TD Cowen cites solid Q1 performance offset by execution risks. The company exceeded revenue expectations due to Merck contributions but relies on future partnerships and revenue from its ECO platform. Upcoming milestones, including the TIDES presentation and GMP facility retrofit, are crucial but their impact remains uncertain, justifying the neutral stance.

Tip Ranks

Merck

VG Health

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

iShares US Medical Devices

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

iShares Global Healthcare

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

Codexis: Neutral Stance Maintained as Execution Risks Offset Solid Q1; $2 Price Target Reaffirmed

Earnings Watch

Codexi | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 15.25 M

Codexis, Inc. (NASDAQ:CDXS) experienced a 35.6% decrease in short interest in March, totaling 6,938,356 shares as of March 31st. This decline reflects 7.8% of the company's stock being short sold, with a short-interest ratio of 4.3 days based on an average trading volume of 1,619,247 shares. The company reported earnings of $0.11 per share for the last quarter, exceeding estimates, and has a market cap of $209 million. Analysts have mixed ratings, with an average target price of $5.00.

Market Beat

Stifel Financial

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Codexis, Inc. (NASDAQ:CDXS) Short Interest Down 35.6% in March

CLDX

Aberdeen Group plc increased its stake in Codexis, Inc. (NASDAQ:CDXS) by 94.7% in Q4, owning 7,966,498 shares valued at approximately $12.99 million. Other institutional investors, including Opaleye Management and Vanguard Group, also raised their holdings. Codexis has a market cap of $179.92 million and reported a quarterly EPS of $0.11, exceeding estimates. Analysts have mixed ratings on the stock, with a consensus rating of "Hold" and a target price of $5.00. Codexis specializes in enzyme solutions for various applications.

Celldex Therap

Aberdeen Group plc Raises Stake in Codexis, Inc. $CDXS

Jefferies analyst assigned a Buy rating to Codexis today and set a price target of $3.50.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The word on The Street in general, suggests a Strong Buy analyst consensus rating for Codexis with a $5.50 average price target.

Codexis (CDXS) Gets a Buy from Jefferies

Codexis, Inc. (NASDAQ:CDXS) is one of the 10 Best High-Risk Penny Stocks to Buy Right Now. On March 12, Matt Hewitt of Craig-Hallum reiterated his Buy rating on Codexis, Inc. (NASDAQ:CDXS). Just a day prior to this, TD Cowen analyst Brendan Smith also maintained his Hold rating on the stock with a price target of […]

Analyst sentiment unchanged after Codexis (CDXS) earnings

Codexis, Inc. (NASDAQ:CDXS) experienced a 26.2% increase in short interest in February, totaling 9,161,843 shares. Currently, 10.3% of its shares are short sold, with a days-to-cover ratio of 8.5 days based on an average daily volume of 1,071,941 shares. Analysts have mixed ratings, with an average price target of $5.00. The company reported $0.11 EPS for the last quarter, exceeding estimates, and had revenue of $38.92 million. Institutional investors hold 78.54% of the stock, indicating strong institutional interest.

Short Interest in Codexis, Inc. (NASDAQ:CDXS) Grows By 26.2%

Codexis (CDXS) has gained attention after reporting Q4 2025 results with revenue of $38.92 million and net income of $9.6 million, alongside new revenue guidance for 2026. The company signed a manufacturing agreement for siRNA, contributing to its RNA capabilities. The stock price rose 30.89% over 7 days, with a fair value estimate of $2.00, indicating it may be undervalued by 19.5%. However, risks include potential delays in scaling production and volatility in revenue. Investors are encouraged to consider broader opportunities in the healthcare sector.

Simplywall

Assessing Codexis (CDXS) Valuation After Strong Earnings And New ECO Synthesis siRNA Agreement

Codexi(CDXS.US)